Novartis AG’s CAR-T cell therapy for leukemia approved by FDA in ‘historic action’; price to be based on outcomes – MarketWatch
Business Insider |
Novartis AG's CAR–T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomes
MarketWatch Novartis AG's NVS, -1.01% CAR–T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute … Novartis receives first ever FDA approval for a CAR–T cell therapy, Kymriah(TM) (CTL019), for children and young … FDA approval brings first gene therapy to the United States A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved |
